TTC edges IMS further into pharma R&D space

Share this article:
Andrew Kress
Andrew Kress

Responding to what it calls a growing need for data and analytics to improve clinical trials, IMS Health acquired TTC, a Philadelphia-based trial benchmarking and analytics firm. Terms were not disclosed.

TTC's tools aim to enhance the speed, efficiency and cost-effectiveness of pharma's clinical trial planning and management activities. Clients include 17 of the top 20 pharmaceutical companies and eight of the 10 largest contract research organizations, according to a statement.

TTC's benchmark data and budgeting/negotiation services will be offered through IMS's clinical trial optimization unit, part of the marketing research firm's healthcare value solutions division.

“This acquisition marks an important step in further expanding IMS's capabilities in the pharma R&D space,” said Andrew Kress, SVP of the division. The purchase follows IMS's April 2012 acquisition of DecisionView, a clinical trial planning and performance firm, and SDI Health, which was cleared by regulators last December.

Harold Glass, PhD, TTC president and CEO, will serve as an an advisor as IMS transitions the business.

Adds Linda Drumright, general manager of IMS's clinical trial optimization unit, “There is growing demand for more data and analytics to optimize the clinical trial process.” She said TTC's analytical tools can help “at a time when the industry faces significant challenges and requires new approaches.”
Share this article:
close

Next Article in Agency Gallery

Email Newsletters

More in Agency Gallery

Private View: Creating Compelling Experiences

Private View: Creating Compelling Experiences

In today's multi-channel environment, game-changing ideas blend creativity and sensory ideation to create a meaningful customer experience

Putting consumers at the center of your universe

Putting consumers at the center of your universe

The question should be: How do you simplify and identify the moments that mean the most to customers?

Did "pay-to-play" confab help Zohydro approval?

Did "pay-to-play" confab help Zohydro approval?

US senators Joe Manchin (D-WV) and David Vitter (R-LA) are asking whether a "pay-to-play" meeting between drug industry executives and FDA officials influenced the agency's approval of Zohydro